LigoCyte Pharmaceuticals ligocyte.com


Public lists: Pharma Startups (4732)

Ligocyte focuses on cellular immunology and new approaches to fight dangerous pathogens. The company's lead programs include vaccines against norovirus, anthrax and influenza.

Ligocyte focuses on cellular immunology and new approaches to fight dangerous pathogens. The company's lead programs include vaccines against norovirus, anthrax and influenza.

Company (Acquired)

Phone: 406-585-2733

Fax:

2155 Analysis Drive

Bozeman, 59718
Montana, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
LigoCyte Pharmaceuticals $57.2M Oct 8, 2012
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related LigoCyte Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 15 investors

Competitors

Company Status Description Investors

Glaukos

Laguna Hills, California, United States
IPO / Went publicGlaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world's leading causes of blindness. We have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm.Login to see details

CVRx

Minneapolis, Minnesota, United States
Alive / ActiveCVRx is a privately held company founded in 2001 and headquartered in Minneapolis, Minnesota. The company has developed the second-generation BAROSTIM NEO, a minimally-invasive implantable system and the only device CE Marked for the separate indications of heart failure and resistant hypertension. BAROSTIM NEO is commercially available in over 20 countries and under clinical evaluation for the treatment of heart failure and hypertension in the United States. The company's BAROSTIM NEO LEGACY ho...Show allLogin to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Method of conferring a protective immune response to norovirus Mar 15, 2013 Nov 21, 2017 Patent
Parenteral norovirus vaccine formulations Mar 15, 2013 Oct 31, 2017 Patent
Norovirus vaccine formulations Mar 15, 2013 Apr 12, 2016 Patent
Norovirus vaccine formulations Mar 15, 2013 Mar 01, 2016 Patent
Anthrax antigens and methods of use Feb 11, 2005 Apr 02, 2013 Patent
See all 7 patents